Poseida Therapeutics (NASDAQ:PSTX) Receives “Market Perform” Rating from William Blair

Poseida Therapeutics (NASDAQ:PSTX)‘s stock had its “market perform” rating reaffirmed by equities research analysts at William Blair in a research note issued to investors on Tuesday, MarketBeat Ratings reports.

Separately, HC Wainwright reiterated a “neutral” rating and set a $9.00 target price (down from $20.00) on shares of Poseida Therapeutics in a research report on Tuesday. Four equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $9.50.

Poseida Therapeutics Price Performance

NASDAQ:PSTX opened at $9.33 on Tuesday. The firm has a market cap of $909.35 million, a PE ratio of -14.81 and a beta of 0.54. Poseida Therapeutics has a 12 month low of $1.87 and a 12 month high of $9.42. The company has a quick ratio of 3.20, a current ratio of 3.20 and a debt-to-equity ratio of 0.68. The company’s 50-day moving average price is $3.02 and its two-hundred day moving average price is $3.01.

Insider Transactions at Poseida Therapeutics

In other news, Chairman Mark J. Gergen sold 30,000 shares of the company’s stock in a transaction that occurred on Tuesday, November 26th. The shares were sold at an average price of $9.27, for a total transaction of $278,100.00. Following the transaction, the chairman now directly owns 651,291 shares in the company, valued at approximately $6,037,467.57. This represents a 4.40 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 2.90% of the stock is owned by company insiders.

Institutional Investors Weigh In On Poseida Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the business. Vanguard Group Inc. raised its stake in shares of Poseida Therapeutics by 16.3% during the first quarter. Vanguard Group Inc. now owns 3,373,065 shares of the company’s stock worth $10,760,000 after buying an additional 473,746 shares during the last quarter. State Street Corp raised its stake in shares of Poseida Therapeutics by 2.3% during the third quarter. State Street Corp now owns 1,710,565 shares of the company’s stock worth $4,892,000 after buying an additional 38,770 shares during the last quarter. Blair William & Co. IL raised its stake in shares of Poseida Therapeutics by 14.1% during the second quarter. Blair William & Co. IL now owns 1,101,325 shares of the company’s stock worth $3,216,000 after buying an additional 136,273 shares during the last quarter. Renaissance Technologies LLC raised its stake in shares of Poseida Therapeutics by 53.4% during the second quarter. Renaissance Technologies LLC now owns 854,900 shares of the company’s stock worth $2,496,000 after buying an additional 297,500 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. raised its stake in shares of Poseida Therapeutics by 89.4% during the first quarter. Jacobs Levy Equity Management Inc. now owns 830,127 shares of the company’s stock worth $2,648,000 after buying an additional 391,801 shares during the last quarter. 46.87% of the stock is owned by institutional investors.

Poseida Therapeutics Company Profile

Poseida Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications.